Merck Stock News

In the most recent trading session, Merck (MRK) closed at $126.96, indicating a -0.15% shift from the previous trading day.

The buy-and-hold strategy serves as the biggest source of wealth creation in the markets. However, it requires research and high conviction to hold through the good and bad times.

Merck: A Great Dividend Growth Stock, But Not At This Price

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Despite markets continuing at record highs, Charles Schwab (NYSE: SCHW ) Investment Management still identifies investment opportunities within long-term stocks. According to its recent filings, the r

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income.

Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing

Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions comman

Amid a frenzy for AI-related stocks, shares of a little-known biotech company in South Korea got an Nvidia-esque boost. Alteogen, a pharmaceutical company with nothing to do with AI, saw its share pri

2 Dow Stocks That Have Been Most Overbought Since The 1970s

Tuesday's U.S. Consumer Price Index ( CPI ) inflation report showed inflation rising faster than expected in January. The cost of housing increased by 0.6%, indicating underlying inflation pressures r

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re

Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.

U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.